Gold bars to be exempt from tariffs, White House clarifies
MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) announced Wednesday that its Board of Directors has approved a quarterly dividend of $0.08 per share for the quarter ended June 30, 2025. According to InvestingPro data, the company has maintained dividend payments for 18 consecutive years, with a current annual dividend yield of 0.59%.
The dividend will be payable on August 29, 2025, to shareholders of record as of August 18, 2025, according to a company press release. The board will consider future cash dividends on a quarterly basis.
Bio-Techne, a global life sciences company that provides tools and bioactive reagents for research and clinical diagnostic communities, generated approximately $1.2 billion in net sales during fiscal 2025 and employs about 3,100 people worldwide.
The company’s products support scientific investigations into biological processes and disease progression, while also assisting in drug discovery efforts and providing means for clinical tests and diagnoses.
This dividend announcement comes as part of the company’s regular quarterly financial activities. The information was disclosed in a press release statement from the company.
In other recent news, Bio-Techne Corporation has entered into an agreement to sell its Exosome Diagnostics business to mdxhealth SA. This deal includes the ExoDx Prostate test and related assets, while Bio-Techne retains access to the exosome-based technology for further kit development. Additionally, Bio-Techne has formed a strategic partnership with Spear Bio to expand global access to SPEAR UltraDetect immunoassay technology, focusing on biomarkers for neurodegenerative disease research. Analyst activity around Bio-Techne has been notable, with Scotiabank lowering its price target to $75, citing a wide range of potential growth rates by fiscal year 2026. Meanwhile, Stifel has maintained its Hold rating with a $60 price target, reflecting a constructive tone from company leadership despite broader sector challenges. Benchmark analysts continue to support a Buy rating, with a $75 price target, while adjusting revenue and earnings estimates for the fourth quarter of fiscal year 2025. They now forecast revenues of $315 million, a 3% increase from the previous year, and revised earnings of $0.50 per share. These developments highlight ongoing strategic maneuvers and analyst assessments impacting Bio-Techne.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.